Schizophrenia-associated risk and protective variants of c-Fos encoding gene

Recent Advances in DNA and Gene Sequences

Volumn 9, Issue 1, 2015, Pages 1-7

  Boyajyan, Anna ^a   Zakharyan, Roksana ^a   Atshemyan, Sofi ^a   Chavushyan, Andranik ^a   Mkrtchyan, Gohar ^a  

^a H Buniatian Institute of Biochemistry National Academy of Sciences of Armenia   (Armenia)

Author keywords

c Fos protein; FOS gene; Genetic polymorphisms; Plasma levels; Schizophrenia; Synaptic plasticity

Indexed keywords

DNA; PROTEIN C FOS; GENOMIC DNA;

ADULT; ARMENIAN (PEOPLE); ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; NERVE CELL PLASTICITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; ALLELE; ARMENIA; CAUCASIAN; CLINICAL FEATURE; DEMOGRAPHY; FEMALE; MALE; MIDDLE AGED; ONCOGENE C FOS; AGED; GENETIC PREDISPOSITION; GENETICS; PATHOLOGY; RISK FACTOR;

ADULT; AGED; ALLELES; ARMENIA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEURONAL PLASTICITY; PROTO-ONCOGENE PROTEINS C-FOS; RISK FACTORS; SCHIZOPHRENIA;

EID: 84937144089     PISSN: 23520922     EISSN: 23520930     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Frankle WG, Lerma J, Laruelle M. The synaptic hypothesis of schizophrenia. Neuron 2003; 39: 205-15.
2. Silva AJ. Molecular and cellular cognitive studies of the role of synaptic plasticity in memory. J Neurobiol 2003; 54: 224-37.
3. Eastwood SL. The synaptic pathology of schizophrenia: is aberrant neurodevelopment and plasticity to blame. Int Rev Neurobiol 2004; 59: 47-72.
4. Stephan KE, Baldeweg T, Friston KJ. Synaptic plasticity and dysconnection in schizophrenia. Biol Psychiatry 2006; 59: 929-39.
5. Bowie CR, Harvey PD. Cognitive deficits and functional outcome in schizophrenia. Neuropsychiatr Dis Treat 2008; 2: 531-6.
6. Takamiya K. Molecular mechanisms of synaptic plasticity underlying learning and memory. Seikagaku 2011; 83: 1016-26.
7. Yin DM, Chen YJ, Sathyamurthy A, Xiong WC, Mei L. Synaptic dysfunction in schizophrenia. Adv Exp Med Biol 2012; 970: 493-516.
8. Ressler KJ, Paschall G, Zhou X, Davis M. Regulation of synaptic plasticity genes during consolidation of fear conditioning. J Neurosci 2002; 22(18): 7892-902.
9. Alberini CM. Transcription factors in long-term memory and synaptic plasticity. Physiol Rev 2009; 89: 121-45.
10. Vanhoutte P, Barnier JV, Guibert B et al. Glutamate induces phosphorylation of Elk-1 and CREB, along with c-fos activation, via an extracellular signal-regulated kinase-dependent pathway in brain slices. Mol Cell Biol 1999; 19: 136-46.
11. Bartzokis G. Schizophrenia: breakdown in the well-regulated lifelong process of brain development and maturation. Neuropsychopharmacology 2002; 27: 672-83.
12. Fatemi SH, Folsom TD. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr Bull 2009; 35: 528-48.
13. Torkamani A, Dean B, Thomas EA. Coexpression network analysis of neural tissue reveals perturbations in developmental processes in schizophrenia. Genome Res 2010; 20: 403-12.
14. Zhao C, Li M. Neuroanatomical substrates of the disruptive effect of olanzapine on rat maternal behavior as revealed by c-Fos immunoreactivity. Pharmacol Biochem Behav 2012; 103: 174-80.
15. Zamberletti E, Viganò D, Guidali C, Rubino T, Parolaro D. Longlasting recovery of psychotic-like symptoms in isolation-reared rats after chronic but not acute treatment with the cannabinoid antagonist AM251. Int J Neuropsychopharmacol 2012; 15: 267-80.
16. Brady AM, Saul RD, Wiest MK. Selective deficits in spatial working memory in the neonatal ventral hippocampal lesion rat model of schizophrenia. Neuropharmacology 2010; 59: 605-11.
17. Fleischmann A, Hvalby O, Jensen V et al. Impaired long-term memory and NR2A-type NMDA receptor-dependent synaptic plasticity in mice lacking c-Fos in the CNS. J Neurosci 2003; 23: 9116-22.
18. Kristiansen LV, Huerta I, Beneyto M, Meador-Woodruff JH. NMDA receptors and schizophrenia. Curr Opin Pharmacol 2007; 7: 48-55.
19. Glover JN, Harrison SC. Crystal structure of the heterodimeric bZIP transcription factor c-Fos-c-Jun bound to DNA. Nature 1995; 373: 257-61.
20. Sanyal S, Sandstrom DJ, Hoeffer CA, Ramaswami M. AP-1 functions upstream of CREB to control synaptic plasticity in Drosophila. Nature 2002; 416: 870-4.
21. Glyvuk N, Tsytsyura Y, Geumann C et al. AP-1/sigma1B-adaptin mediates endosomal synaptic vesicle recycling, learning and memory. EMBO J 2010; 29: 1318-30.
22. Dwyer ND, Adler CE, Crump JG, L'Etoile ND, Bargmann CI. Polarized dendritic transport and the AP-1 mu1 clathrin adaptor UNC-101 localize odorant receptors to olfactory cilia. Neuron 2001; 31: 277-87.
23. Horikawa HP, Kneussel M, El Far O, Betz H. Interaction of synaptophysin with the AP-1 adaptor protein gamma-adaptin. Mol Cell Neurosci 2002; 21: 454-62.
24. Ameyar M, Wisniewska M, Weitzman JB. A role for AP-1 in apoptosis: the case for and against. Biochimie 2003; 85: 747-52.
25. Pennypacker KR. AP-1 transcription factor complexes in CNS disorders and development. J Fla Med Assoc 1995; 82: 551-4.
26. Medicherla R, Leers-Sucheta S, Luo Y, Azhar S. Impaired activation of AP-1 and altered expression of constituent proteins in rat adrenal during ageing. Mech Ageing Dev 2001; 122: 1169-86.
27. Smith DR, Hoyt EC, Gallagher M, Schwabe RF, Lund PK. Effect of age and cognitive status on basal level AP-1 activity in rat hippocampus. Neurobiol Aging 2001; 22: 773-86.
28. Raivich G, Behrens A. Role of the AP-1 transcription factor c-Jun in developing, adult and injured brain. Prog Neurobiol 2006; 78: 347-63.
29. Kyosseva SV. Differential expression of mitogen-activated protein kinases and immediate early genes fos and jun in thalamus in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 997-1006.
30. Boyajyan A, Zakharyan R, Khoyetsyan A. In: Sumiyoshi T, Ed. Schizophrenia Research: Recent Advances. New York: Nova Science Publishers Inc 2012: pp.183-240.
31. Zakharyan R, Boyajyan A. Inflammatory cytokine network in schizophrenia. World J Biol Psychiatry 2014; 15: 174-87.
32. Lee YN, Tuckerman J, Nechushtan H, Schutz G, Razin E, Angel P. c-Fos as a regulator of degranulation and cytokine production in FcεRI-activated mast cells. J Immunol 2004; 173: 2571-7.
33. Adcock IM, Caramori G. Cross-talk between pro-inflammatory transcription factors and glucocorticoids. Immunol Cell Biol 2001; 79: 376-84.
34. Hae JP, Jong WK, Byoung-Soo C, Joo-Ho C. Association of FOSlike antigen 1 promoter polymorphism with podocyte foot process effacement in immunoglobulin A nephropathy patients. Journal of Clinical Laboratory Analysis 2014; 28: 391-7.
35. de Maturana EL, Yes Y, Called ML et al. Application of multi-SNP approaches Bayesian LASSO and AUC-RF to detect main effects of inflammatory-gene variants associated with bladder cancer risk. PLoS One 2013; 8: e83745.
36. Rastaldi MP, Tunesi S, Ferrario F, et al. Transforming growth factor-beta, endothelin-1, and c-fos expression in necrotizing/crescentic IgA glomerulonephritis. Nephrol Dial Transplant 1998; 13: 1668-74.
37. The International Statistical Classification of Diseases and Related Health Problems, ICD-10. 10th ed. Geneva: World Health Organization 1992.
38. Diagnostic and Statistical Manual of Mental Disorders, DSM-IVTR. 4th ed. Arlington: American Psychiatric Association 2000.
39. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders. Non-patient ed. SCID-I/NP. New York: Biometrics Research, New York State Psychiatric Institute 2002.
40. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Research 1988; 16: 1215.
41. Bunce M, O’Neil CM, Barnado MC et al. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 1995; 46: 355-67.
42. Yiu WC, Yap MKH, Fung WY, Ng PW, Yip SP. Genetic susceptibility to refractive error: association of vasoactive intestinal peptide receptor 2 (VIPR2) with high myopia in Chinese. PLoS ONE 2013; 8: e61805.
43. Trofimov VA, Lopukhova EN, Vlasov AP. Prevalence of gene polymorphism c-fos and its expressive activity in the normal conditions and in endotoxicosis]. Fundamental research 2014; 12: 770-3.
44. Huang B1, Liu B, Yang L, Li Y, Cheng M, Huang D, Wang H, Zhang X, Zheng J, Li Q, Ji W, Zhou Y, Lu J. Functional genetic variants of c-Jun and their interaction with smoking and drinking increase the susceptibility to lung cancer in southern and eastern Chinese. Int J Cancer 2012; 131: E744-58.
45. Kontkanen O, Lakso M, Wong G, Castrén E. Chronic antipsychotic drug treatment Park HJ, Kim JW, Cho BS, Chung JH. Association of FOS-like antigen 1 promoter polymorphism with podocyte foot process effacement in immunoglobulin A nephropathy patients. J Clin Lab Anal 2014; 28: 391-7.
46. Fernández-Rozadilla C, Tarrío R, Clofent J et al. Colorectal cancer susceptibility quantitative trait loci in mice as a novel approach to detect low-penetrance variants in humans: a two-stage case-control study. Cancer Epidemiol Biomarkers Prev 2010; 19: 619-23.
47. Yang SK, Hong M, Zhao W et al. Genome-wide association study of Crohn’s disease in Koreans revealed three new susceptibility loci and common attributes of genetic susceptibility across ethnic populations. Gut 2014; 63: 80-7.
48. Kontkanen O, Lakso M, Wong G, Castrén E. Chronic antipsychotic drug treatment induces long-lasting expression of fos and jun family genes and activator protein 1 complex in the rat prefrontal cortex. Neuropsychopharmacology 2002; 27: 152-62.
49. Nguyen TV, Kosofsky BE, Birnbaum R, Cohen BM, Hyman SE. Differential expression of c-fos and zif268 in rat striatum after haloperidol, clozapine, and amphetamine. Proc Natl Acad Sci USA 1992; 89: 4270-4.
50. Miller JC, Mathé AA. Basal and stimulated c-fos mRNA expression in the rat brain: effect of chronic dietary lithium. Neuropsychopharmacology 1997; 16: 408-18.
51. Robertson GS, Fibiger HC. Neuroleleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 1992; 46: 315-28.
52. Zhao C, Li M. C-Fos Identification of neuroanatomical sites associated with haloperidol and clozapine disruption of maternal behavior in the rat. Neuroscience 2010; 166: 1043-55.
53. Hussain N, Flumerfelt BA, Rajakumar N. Glutamatergic regulation of haloperidol-induced c-fos expression in the rat striatum and nucleus accumbens. Neuroscience 2001; 102: 391-9.
54. Lee J, Rajakumar N. Role of NR2B-containing N-methyl-Daspartate receptors in haloperidol-induced c-Fos expression in the striatum and nucleus accumbens. Neuroscience 2003; 122: 739-45.
55. Yanahashi S, Hashimoto K, Hattori K, Yuasa S, Iyo M. Role of NMDA receptor subtypes in the induction of catalepsy and increase in Fos protein expression after administration of haloperidol. Brain Res 2004; 1011: 84-93.
56. Marin C1, Bonastre M, Tolosa E. Striatal c-fos levels do not correlate with haloperidol-induced behavioral supersensitivity. Synapse 1996; 23: 89-93.
57. Merchant KM, Dobie DJ, Filloux FM, Totzke M, Aravagiri M, Dorsa DM. Effects of chronic haloperidol and clozapine treatment on neurotensin and c-fos mRNA in rat neostriatal subregions. J Pharmacol Exp Ther 1994; 271(1): 460-71.
58. Cherñavsky AC1, Valerani AV, Burdman JA. Haloperidol and oestrogens induce c-myc and c-fos expression in the anterior pituitary gland of the rat. Neurol Res 1993; 15(5): 339-43.
59. Colotta F, Polentarutti N, Wang JM, Mantovani A. c-Fos protooncogene expression in human normal peripheral blood leukocytes. Cytotechnology 1987; 1: 61-4.